Regeneron Pharmaceuticals REGN Stock
Regeneron Pharmaceuticals Price Chart
Regeneron Pharmaceuticals REGN Financial and Trading Overview
| Regeneron Pharmaceuticals stock price | 920.69 USD |
| Previous Close | 922.4 USD |
| Open | 936.37 USD |
| Bid | 955.62 USD x 100 |
| Ask | 975 USD x 2500 |
| Day's Range | 916.66 - 948.42 USD |
| 52 Week Range | 591.52 - 991.73 USD |
| Volume | 856.78K USD |
| Avg. Volume | 804.03K USD |
| Market Cap | 95.24B USD |
| Beta (5Y Monthly) | 0.095 |
| PE Ratio (TTM) | 20.351236 |
| EPS (TTM) | 45.24 USD |
| Forward Dividend & Yield | 3.76 (0.41%) |
| Ex-Dividend Date | November 20, 2026 |
| 1y Target Est | 991 USD |
REGN Valuation Measures
| Enterprise Value | 86.06B USD |
| Trailing P/E | 20.351236 |
| Forward P/E | 12.84823 |
| PEG Ratio (5 yr expected) | 1.15 |
| Price/Sales (ttm) | 5.636972 |
| Price/Book (mrq) | 2.7571678 |
| Enterprise Value/Revenue | 5.094 |
| Enterprise Value/EBITDA | 15.241 |
Trading Information
Regeneron Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.095 |
| 52-Week Change | 22.15% |
| S&P500 52-Week Change | 8.67% |
| 52 Week High | 991.73 USD |
| 52 Week Low | 591.52 USD |
| 50-Day Moving Average | 826.97 USD |
| 200-Day Moving Average | 750.64 USD |
REGN Share Statistics
| Avg. Volume (3 month) | 804.03K USD |
| Avg. Daily Volume (10-Days) | 916.83K USD |
| Shares Outstanding | 101.63M |
| Float | 96.36M |
| Short Ratio | 2.93 |
| % Held by Insiders | 2.14% |
| % Held by Institutions | 92.34% |
| Shares Short | 2.22M |
| Short % of Float | 2.27% |
| Short % of Shares Outstanding | 2.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 3.7 |
| Trailing Annual Dividend Yield | 0.40% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.08180001 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 28.51% |
| Operating Margin (ttm) | 30.38% |
| Gross Margin | 46.73% |
| EBITDA Margin | 33.41% |
Management Effectiveness
| Return on Assets (ttm) | 7.58% |
| Return on Equity (ttm) | 14.94% |
Income Statement
| Revenue (ttm) | 16.9B USD |
| Revenue Per Share (ttm) | 164.24 USD |
| Quarterly Revenue Growth (yoy) | 36.29% |
| Gross Profit (ttm) | 7.9B USD |
| EBITDA | 5.65B USD |
| Net Income Avi to Common (ttm) | 4.82B USD |
| Diluted EPS (ttm) | 45.24 |
| Quarterly Earnings Growth (yoy) | 33.50% |
Balance Sheet
| Total Cash (mrq) | 9.3B USD |
| Total Cash Per Share (mrq) | 92.69 USD |
| Total Debt (mrq) | 2.71B USD |
| Total Debt/Equity (mrq) | 8.08 USD |
| Current Ratio (mrq) | 3.353 |
| Book Value Per Share (mrq) | 333.926 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 4.85B USD |
| Levered Free Cash Flow (ttm) | 2.58B USD |
Profile of Regeneron Pharmaceuticals
| Country | United States |
| State | NY |
| City | Tarrytown |
| Address | 777 Old Saw Mill River Road |
| ZIP | 10591-6707 |
| Phone | 914 847 7000 |
| Website | https://www.regeneron.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15410 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Q&A For Regeneron Pharmaceuticals Stock
What is a current REGN stock price?
Regeneron Pharmaceuticals REGN stock price today per share is 920.69 USD.
How to purchase Regeneron Pharmaceuticals stock?
You can buy REGN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Regeneron Pharmaceuticals?
The stock symbol or ticker of Regeneron Pharmaceuticals is REGN.
Which industry does the Regeneron Pharmaceuticals company belong to?
The Regeneron Pharmaceuticals industry is Biotechnology.
How many shares does Regeneron Pharmaceuticals have in circulation?
The max supply of Regeneron Pharmaceuticals shares is 103.45M.
What is Regeneron Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Regeneron Pharmaceuticals PE Ratio is 20.35123600 now.
What was Regeneron Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Regeneron Pharmaceuticals EPS is 45.24 USD over the trailing 12 months.
Which sector does the Regeneron Pharmaceuticals company belong to?
The Regeneron Pharmaceuticals sector is Healthcare.
Regeneron Pharmaceuticals REGN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
22617.73 USD — |
-5.28
|
10.6B USD — | 22513.01 USD — | 23837.76 USD — | — - | 10.6B USD — |
S&P 500 (Yahoo.com)
GSPC
US
|
6910.39 USD — |
-3.7
|
4.73B USD — | 6882.66 USD — | 7198.67 USD — | — - | 4.73B USD — |
US100
NDX
US
|
25028.98 USD — |
-5.61
|
2.69B USD — | 24910.48 USD — | 26429.09 USD — | — - | 2.69B USD — |
S&P 500 INDEX
SPX
US
|
6910.39 USD — |
-3.7
|
505.58M USD — | 6882.66 USD — | 7198.67 USD — | — - | 505.58M USD — |
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3815.19 USD — |
-1.22
|
121.01M USD — | 3805.63 USD — | 3911.38 USD — | — - | 121.01M USD — |
US Tech Health Care
IXHC
US
|
1282.67 USD — |
-1.79
|
— — | 1279.99 USD — | 1317.94 USD — | — - | — — |
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
2214.31 USD — |
-0.8
|
— — | 2209.33 USD — | 2262.42 USD — | — - | — — |
US Tech Global Select Market Com
NQGS
US
|
11139.01 USD — |
-5.31
|
— — | 11086.73 USD — | 11742.47 USD — | — - | — — |
US Tech DM Ex Japan Large Mid Ca
NQDMXJPLMAUD
US
|
2100.38 AUD 1467.26 USD |
<0.01
|
— — | 2100.38 AUD 1467.26 USD | 2100.38 AUD 1467.26 USD | — - | — — |
US Tech-100 PM Settlement Value
XQC
US
|
16331.98 USD — |
+1.13
|
— — | 16331.98 USD — | 16331.98 USD — | — - | — — |
The Capital Strength Index
NQCAPST
US
|
3680.28 USD — |
-0.78
|
— — | 3672.87 USD — | 3759.02 USD — | — - | — — |
US Tech-100 Notional Net Total R
XNDXNNR
US
|
29196.94 USD — |
-5.6
|
— — | 29058.69 USD — | 30830.08 USD — | — - | — — |
US Tech-100 ESG Net Notional Tot
NDXESG24
US
|
2058.89 EUR 2259.54 USD |
-5.84
|
— — | 2051.84 EUR 2251.8 USD | 2178.71 EUR 2391.04 USD | — - | — — |
US Tech-100 Micro Index
XND
US
|
250.29 USD — |
-5.61
|
— — | 249.11 USD — | 264.29 USD — | — - | — — |
US Tech-100 Equal Weighted
NDXE
US
|
8899.48 USD — |
-4.18
|
— — | 8869.11 USD — | 9299.32 USD — | — - | — — |
US Tech Composite Total Return
XCMP
US
|
27958.09 USD — |
-5.28
|
— — | 27828.65 USD — | 29466.09 USD — | — - | — — |
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
US Tech-100 Pre Market Indicator
QMI
US
|
26284.09 USD — |
-0.88
|
— — | 25923.02 USD — | 26284.09 USD — | — - | — — |
US Tech-100 Reduced Value Index
NQX
US
|
5005.8 USD — |
-5.61
|
— — | 4982.1 USD — | 5285.86 USD — | — - | — — |
US Tech US Price Setters Index
NQPRCE
US
|
3057.59 USD — |
-1.54
|
— — | 3050.97 USD — | 3134.72 USD — | — - | — — |


